<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292835</url>
  </required_header>
  <id_info>
    <org_study_id>ALG 17/003</org_study_id>
    <nct_id>NCT03292835</nct_id>
  </id_info>
  <brief_title>Complex Cutaneous Leishmaniasis Healing Study in Algeria</brief_title>
  <acronym>LeiClean</acronym>
  <official_title>Multicentric Non-Interventional Trial Evaluating Painless Hand Hygiene and LeiProtect® Dressing to Treat Complex Cutaneous Leishmaniasis in Algeria - LeiClean</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K. W. Stahl</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Waisenmedizin e. V. Promoting Access to Essential Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of clean wound management and dressing on complex zoonotic&#xD;
      cutaneous leishmaniasis caused by L. major in the MENA region (Algeria). The patients will&#xD;
      participate in the wound dressing themselves. The objective is to determine the amount of&#xD;
      patients that can avoid systemic chemotherapy with pentavalent antimony which is compulsory&#xD;
      for patients with complex CL lesions. In Algeria, this requires expensive hospital care&#xD;
      because of the eventual toxic side effects of Sb(V).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator initiated, non-interventional LeiClean Trial with 100 CL patients presenting&#xD;
      complex CL lesions, normally in need of a systemic an in-door treatment with meglumine&#xD;
      antimoniate and in risk of systemic antimony toxicity (see inclusion criteria!) during the CL&#xD;
      season of 2017/18 is part of the renewed cooperation treaty between the IPA and WM e. V. and&#xD;
      originates from encouraging compassionate use observations after topical LeiClean treatment&#xD;
      authorized by the Algerian Ministry of Health in December 2015. The study will be carried out&#xD;
      in the ZCL region of M'Sila and Bou Saada.&#xD;
&#xD;
      The German Regulation Authority, BfArM, has granted a special approval according to §11 MPG&#xD;
      (German regulation for Medical Devices) to the new filmogenic gel dressing LeiProtect®. The&#xD;
      patients with complex cutaneous leishmaniasis (Giemsa and PCR confirmed) elected for indoor&#xD;
      treatment with systemic antimony treatment are given the option for a LeiClean treatment of&#xD;
      their lesions; they are instructed on hand hygiene and LeiProtect® dressing of their lesions&#xD;
      which they carry out themselves at home during seven days. On day eight they come for lesion&#xD;
      cleansing and photographic monitoring before they start another weekly LeiClean cycle. The&#xD;
      patients can at any time opt for a conventional systemic chemotherapeutic treatment in a&#xD;
      hospital if they are not satisfied with their healing progress. However, if the doctor&#xD;
      realizes that after two months the hygienic wound management results in inadequate healing,&#xD;
      he can also order hospital for the patients. The doctor will allow the patients to visualise&#xD;
      their healing progress over the course of the trial through digital images on the computer.&#xD;
&#xD;
      After complete epithelisation of the lesions, the patients come for controls at monthly&#xD;
      intervals up to a period of five months to check for eventual lesion relapses. The costs of&#xD;
      the LeiClean outdoor treatment will be evaluated and compared to the already known hospital&#xD;
      costs per patient for a three-week systemic indoor Sb(V) treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Political Issues in Algeria and now Covod-19 lock-down&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Lesion Epithelisation</measure>
    <time_frame>2 months</time_frame>
    <description>Digital photo documentation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No healing progress with LeiClean</measure>
    <time_frame>2 months</time_frame>
    <description>Patients who have to be hospitalised for systemic Sb(V) treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cutaneous Leishmaniases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LeiProtect®</intervention_name>
    <description>Filmogenic dressing gel</description>
    <other_name>Alcohol Based Hand-Rub (ABHR)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Polymerase Chain Reaction (PCR). The differentiation of parasite species in between&#xD;
      responders and eventual non-responders using sequencing technologies established in the&#xD;
      Institute of Clinical Microbiology, Immunology and Hygiene, FAU Erlangen and University&#xD;
      Hospital Erlangen.&#xD;
&#xD;
      Smears with Giemsa staining.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ZCL patients in the CL endemic region of M'Sila and Bou Saada, Algeria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has Giemsa and PCR proven L.major cutaneous leishmaniasis&#xD;
&#xD;
          -  Subject has complex zoonotic cutaneous leishmaniasis or Sb(V) incompatibility&#xD;
&#xD;
          -  Subject gives voluntary consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immune deficiencies, skin tumours, allergy to 1,2-propylene glycol (rare)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoubir Harrat, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pasteur Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NGO Waisenmedizin e. V.</name>
      <address>
        <city>Freiburg</city>
        <zip>79100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
  </removed_countries>
  <link>
    <url>http://www.waisenmedizin.org</url>
    <description>Organisation Homepage</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Waisenmedizin e. V. Promoting Access to Essential Medicine</investigator_affiliation>
    <investigator_full_name>K. W. Stahl</investigator_full_name>
    <investigator_title>Prof. Dr. Dr.</investigator_title>
  </responsible_party>
  <keyword>complex</keyword>
  <keyword>zoonotic</keyword>
  <keyword>medical device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

